How much does Sotorasib cost?

Sotorasib (Sotorasib) is a new type of targeted therapy drug that belongs to the category of KRAS G12C inhibitors. KRASGene mutations are common in a variety of cancers, including non-small cell lung cancer (NSCLC). Sotoracib is unique in that it specifically targets the KRAS geneG12C mutation, a specific genetic variant that is prevalent in patients with NSCLC.

The original drug of sotorasibu has not yet been launched in China, so patients cannot purchase it domestically and need to purchase sotorasibu through overseas channels. The price of the original version of sotorasibu in Hong Kong, China, with the specifications of 120mg*240 tablets, is around 8 million, and the price of the European version of the original drug with the same specifications is around 4 million, which is relatively expensive. The cheaper ones are the generic drugs marketed abroad. For example, the price of generic drugs in Laos and Bangladesh is around two to three thousand yuan. The price is relatively cheap, and the ingredients of foreign generic drugs are basically the same as the original drugs.

The KRAS gene plays an important regulatory role in cells and is involved in cell growth and differentiation. However, when the KRAS gene undergoes a G12C mutation, it loses its normal growth-regulating function, leading to abnormal cell proliferation and eventually the formation of cancer. Sotoracib acts directly on the KRAS G12C mutation and inhibits its activity, thereby blocking the growth signaling pathway of cancer cells and providing new hope for treatment.

Clinical trial results show that sotorasiib has a significant therapeutic effect in some KRAS G12C mutated NSCLC patients. Its development represents a breakthrough in the field of KRAS gene therapy, because scientists have long believed that directly interfering with the KRAS gene is a difficult task.